Lynne M. Mitchell

发表

Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2

Gregory F. Wu, S. Whelan, D. Perantie, 2021, Annals of Internal Medicine.

The complement protein properdin binds apoptotic T cells and promotes complement activation and phagocytosis

D. Hourcade, Lijuan Zhang, C. Kemper, 2008, Proceedings of the National Academy of Sciences.

Properdin Can Initiate Complement Activation by Binding Specific Target Surfaces and Providing a Platform for De Novo Convertase Assembly1

D. Hourcade, J. Atkinson, D. Spitzer, 2007, The Journal of Immunology.

Novo Convertase Assembly Surfaces and Providing a Platform for De Activation by Binding Specific Target Properdin Can Initiate Complement

D. Hourcade, J. Atkinson, D. Spitzer, 2007 .

Characterization of the active site in Decay-Accelerating Factor (DAF)

D. Hourcade, L. Kuttner-Kondo, M. Medof, 2000 .

Deep phenotyping detects a pathological CD4+ T-cell complosome signature in systemic sclerosis

S. Heck, T. Woodruff, D. Hourcade, 2020, Cellular & Molecular Immunology.

Title: Deep-phenotyping detects a pathological CD4 + T cell complosome signature in 1 systemic sclerosis 2 Running Title: A novel pathogenic T cell signature in scleroderma

Nocerino, S. Heck, T. Woodruff, 2019 .

Anti-complement activity of the Ixodes scapularis salivary protein Salp20.

D. Hourcade, C. Pham, A. Akk, 2016, Molecular immunology.

Decay acceleration of the complement alternative pathway C3 convertase.

D. Hourcade, L. Mitchell, M. Medof, 1999, Immunopharmacology.

Mutations of the type A domain of complement factor B that promote high-affinity C3b-binding.

D. Hourcade, T. Oglesby, L. Mitchell, 1999, Journal of immunology.

A Conserved Element in the Serine Protease Domain of Complement Factor B*

D. Hourcade, T. Oglesby, L. Mitchell, 1998, The Journal of Biological Chemistry.

High-Affinity C3b-Binding Complement Factor B That Promote Mutations of the Type A Domain of

D. Hourcade, L. Mitchell, J. Teresa, 2013 .

High-Affinity C 3 b-Binding Complement Factor B That Promote Mutations of the Type A Domain of Oglesby

D. Hourcade, L. Mitchell, Lynne M. Mitchell, 1999 .

Synergy between surface and core entrapped metals in a mixed manganese-gadolinium nanocolloid affords safer MR imaging of sparse biomarkers.

S. Caruthers, D. Hourcade, D. Pan, 2015, Nanomedicine : nanotechnology, biology, and medicine.

Variable Antibody-dependent Activation of Complement by Functionalized Phospholipid Nanoparticle Surfaces*

D. Hourcade, S. Wickline, G. Lanza, 2010, The Journal of Biological Chemistry.

Application of a hemolysis assay for analysis of complement activation by perfluorocarbon nanoparticles.

Nathan A. Baker, Nathan A Baker, Gregory M Lanza, 2014, Nanomedicine : nanotechnology, biology, and medicine.

Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2

Gregory F. Wu, S. Whelan, D. Perantie, 2021, medRxiv.

A Corresponding Tyrosine Residue in the C2/Factor B Type A Domain Is a Hot Spot in the Decay Acceleration of the Complement C3 Convertases*

D. Hourcade, J. Atkinson, L. Kuttner-Kondo, 2003, Journal of Biological Chemistry.

Decay-accelerating Factor (DAF), Complement Receptor 1 (CR1), and Factor H Dissociate the Complement AP C3 Convertase (C3bBb) via Sites on the Type A Domain of Bb*

D. Hourcade, J. Atkinson, L. Kuttner-Kondo, 2002, The Journal of Biological Chemistry.

Characterization of the Active Sites in Decay-Accelerating Factor1

D. Hourcade, L. Kuttner-Kondo, L. Mitchell, 2001, The Journal of Immunology.

Elucidating allergic reaction mechanisms in response to SARS-CoV-2 mRNA vaccination in adults.

B. Pulendran, I. Agache, C. Akdis, 2024, Allergy.